country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P11678

Copy Link Print Information

HDAC-IN-100

HDAC-IN-100 is a histone deacetylase inhibitor with an IC₅₀ of 0.038 μM against HDAC1, 0.283 μM against HDAC2, and 0.586 μM against HDAC3. HDAC-IN-100 acts as a chemosensitizer and apoptosis inducer, activates caspase 3/7, and reverses Cisplatin (HY-17394) resistance. HDAC-IN-100 exerts antiproliferative effects in ovarian cancer cells and squamous cancer cells. HDAC-IN-100 is applicable for research related to ovarian cancer, squamous cell carcinoma, and Cisplatin (HY-17394)-resistant squamous cell carcinoma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2390474-88-9
Formel: C₃₂H₃₃N₅O₃
Molecular Weight:535.64

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

HDAC-IN-100 Chemical Structure

CAS. Nr.: 2390474-88-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]

HDAC1

0.038 μM (IC₅₀)

HDAC2

0.283 μM (IC₅₀)

HDAC3

0.586 μM (IC₅₀)

Caspase-3

Caspase-7

Alle HDAC Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.48 μM Compound: 2a	Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and measured after 3 hrs by fluorescence assay Inhibition of HDAC in human A2780 cells using Boc-Lys(epsilon-Ac)-AMC as substrate preincubated for 18 hrs followed by substrate addition and measured after 3 hrs by fluorescence assay	[PMID: 31762274]

In Vitro

HDAC-IN-100 (compound 2a) (72 h) reduces the viability of human cancer cells A2780 (IC₅₀ 2.40 μM) and Cal27 (IC₅₀ 1.60 μM)^[1].
HDAC-IN-100 (0-100 μM; 18 h) potently inhibits cellular HDAC activity in human cancer cells A2780 (IC₅₀ 0.48 μM) and Cal27 (IC₅₀ 0.11 μM)^[1].
HDAC-IN-100 (0.5 μM; 48 h) exerts a strong synergistic effect with Cisplatin (HY-17394) to reduce the viability of Cal27 cells and Cisplatin-resistant Cal27CisR cells, and completely reverses the Cisplatin resistance of Cal27CisR cells^[1].
HDAC-IN-100 (0.5 μM; 48 h) significantly increases the apoptosis levels in Cal27 cells and cisplatin (HY-17394)-resistant Cal27CisR cells^[1].
HDAC-IN-100 (0.5 μM; 24 h) induces hyperacetylation of histone H3 in Cal27 cells and cisplatin (HY-17394)-resistant Cal27CisR cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Human tongue squamous cell carcinoma Cal27 cells, cisplatin-resistant Cal27CisR cells
Concentration:

0.5 μM
Incubation Time:

48 h (pretreatment); 72 h (Cisplatin incubation)
Result:

Reduced the cisplatin IC₅₀ from 9.79 μM to 1.26 μM in Cal27 cells.
Reduced the cisplatin IC₅₀ from 63.2 μM to 8.42 μM in Cal27CisR cells,.
Showed synergistic interaction with Cisplatin, with strong synergism observed at multiple concentration combinations.

Related Protocols :

Chemical Information

CAS. Nr. 2390474-88-9
Molecular Weight 535.64
Formel C₃₂H₃₃N₅O₃
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Krieger V, et al. Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties. J Med Chem. 2019;62(24):11260-11279. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

HDAC-IN-100

Alle HDAC Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen